期刊文献+

支气管哮喘-慢性阻塞性肺疾病重叠综合征265例 被引量:14

Asthma COPD overlap syndrome: retrospective analysis of 265 cases
下载PDF
导出
摘要 目的:研究支气管哮喘-慢性阻塞性肺疾病重叠综合征(asthma COPD overlap syndrome,A COS)的诊治情况。方法 :对265例ACOS及850例单纯哮喘患者从一般情况、危险因素、临床特点、1年内急性加重住院次数及治疗方案方面进行统计分析。结果:ACOS的危险因素为吸烟、FEV1<50%预计值、低收入。ACOS的临床表现均较单纯哮喘组差,1年内急性加重住院次数(≥2次)也增高,85.7%患者应用ICS联合LABA/LAMA治疗。结论:ACOS较单纯哮喘患者病情重,急性加重频繁。吸烟、肺功能差、收入低是其危险因素。ICS联合LABA/LAMA治疗不充分,有待加强。 Objective To investigate diagnosis and treatment of Asthma COPD overlap syndrome (ACOS). Methods Clinical data of the general situation, risk factors, clinical manifestations, frequent exacerbation and hospitalization within one year, treatment between ACOS patients (n = 265) and simple asthma (n = 850) were analysed. Results Smoking, FEV1 〈 50% predicted and low income were risk factors for ACOS. Compared with simple asthma patients, the clinical manifestations of ACOS were worse, and the frequency of exacerbation and hospitalization within one year (twice and above)were higher. ICS combined with LABA/LAMA were applied in 85.7% of ACOS patients. Conclusions Compared with simple asthma, ACOS has the characteristics of high severi- ty, frequent exacerbation. Smoking, poor lung function and low income are the risk factors of ACOS. The applica- tion of ICS combined with LABA/LAMA therapy was inadequate in ACOS patients, which is need to be strengthened.
出处 《实用医学杂志》 CAS 北大核心 2015年第3期437-438,共2页 The Journal of Practical Medicine
基金 吉林省卫生科研计划项目(编号:2013Z051) 白求恩医学科研支持计划-青年科研基金项目(编号:2013206039)
关键词 ACOS 易患因素 临床表现 治疗 ACOS Risk factor Clinical manifestations Treatment
  • 相关文献

参考文献4

  • 1GOLD Executive Committee. Global strategy for the diagnosis,management, and prevention of chronic obstructive pulmonarydisease (Revised 2014)[EB/OL]. [2014-05-08]. http;//www.goldcopd. com.
  • 2Global Initiative for Asthma.The global strategy for astllma man-agement and prevention(Revised 2014) [EB/OL]. [2014-05-08 ] .http ; //www .ginasthma.org.
  • 3Nishiyama 0, Tohda Y. Diagnostic differences in asthma andchronic obstructive pulmonary disease [J]. Kinsho Byori, 2014,62(5):457-463.
  • 4戴晓新,洪旭初.慢阻肺-哮喘重叠综合征及药物治疗现状[J].实用医学杂志,2014,30(14):2189-2190. 被引量:30

二级参考文献19

  • 1Zeki AA, Schivo M, Chan A, et al. The Asthma-COPD overlap syndrome: a common clinical problem in the elderly [J]. J Allergy (Cairo), 2011,2011:861-926.
  • 2Louie S, Zeki AA, Schivo M, et al. The asthma-chronic obstructive puhnonary disease overlap syndrome: pharmacotherapeutic considerations [J]. Expert Rev Clin Pharmacol, 2013,6(2) : 197-219.
  • 3Miravitlles M, Soler-Catalufla JJ, Calle M, et al. Spanish COPD Guidelines (GesEPOC) :Pharmacological treatment of stable COPD [J]. Aten Primaria,2012,44(7) :425-437.
  • 4Soler-Catalufla JJ, Cosio B, Izquierdo JL, et al. Consensus document on the overlap phenotype COPD-asthma in COPD [J]. Arch Bronconeumol, 2012,48(9) :331-337.
  • 5Koblizek V, Chlumsky J, Zindr V, et al. Chronic Obstructive Pulmonary Disease: Official diagnosis and treatment guidelines ofthe Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care [J]. Biomcd Pap Med Fac Univ Palacky Olomouc Czech Repub, 2013,157(2) : 189-201.
  • 6GOLD Executive Committee. Global strategy for the diagnosis, mangement,and prevention of chronic obstructive pulmonary disease (Revised 2011).
  • 7Ai-Kassimi FA, Alhamad EH. Chronic obstructive pulmonary disease lost in translation: Why are the inhaled corticosteroids skeptics refusing to go [ J ] ? Ann Thorac Med, 2013,8 ( 1 ) : 8-13.
  • 8Marc Miravitlles.A new approach to grading and treating COPD based on clinical phenotypes:surmnary of the Spanish COPD guidelines (GesEPOC) [J]. Prim Care Respir J, 2013,22(1): 117-121.
  • 9Hizawa N. Pharmacogeneties of chronic obstructive pulmonary disease [J]. Pharmacogenomics, 2013,14(10) : 1215-1225.
  • 10Ohar JA, Donohue JF. Mono- and combination therapy of long- acting bronehodilators and inhaled eortieesteroids in advanced COPD [J]. Semin Respir Crit Care Med, 2010,31 (3) :321-333.

共引文献29

同被引文献111

  • 1徐杰.噻托溴铵联合大剂量舒利迭治疗重度支气管哮喘合并慢性阻塞性肺疾病的疗效[J].世界临床医学,2017,11(2):116-116. 被引量:11
  • 2HARDIN M, SILVERMAN EK, BARR RG, et al. The clinical features of the overlap between COPD and asthma [J]. Respir Res,2011,12(1): 1-8.
  • 3GOLD Executive Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (Revised 2014). [2014-05-08]. http: //www. goldcopd.com.
  • 4Global Initiative for Asthma. The global strategy for astllma management and prevention ( Revised 2014 ). [ 2014 -05-08 ].
  • 5DE MARCO R, PESCE G, MARCON A, et al. The coexistence of asthma and chronic obstructive pulmonary disease (COPD): prevalence and risk factors in young, middle-aged and elderly people from the general population [J]. PLoS One, 2013, 8 (5): 1224-1230.
  • 6GIBSON PG, SIMPSON JL.The overlap syndrome of asthma and COPD: what are its features and how important is it? [ J]. Thorax, 2009,64 ( 8 ) : 728-735.
  • 7POSTMA DS,KERSTJENS HAM.Characteristics of airway hyperresponsiveness in asthma and chronic obstructive pulmonary disease [J]. Respir Crit Care Med, 1998, 158 (5 Pt 3) :643- 649.
  • 8SCICHILONE N,BATTAGLIA S,LA SALA A,et al.Clinieal implications of airway hyper-responsiveness in COPD [J].Int J Chron Obstruct Pulmon Dis, 2006, 1 ( 1 ) : 49-60.
  • 9RHEE CK,YOON HK,YOO KH,et al. Medical utilization and cost in patients with overlap syndrome of chronic obstructive pulmonary disease and asthma [J].COPD,2014,11 (2) : 163 - 170.
  • 10LOUIE S,ZEKI AA,SCHIVO M,et al. The asthma-chronic obstructive pulmonary disease overlap syndrome : pharmacotherapeutic considerations [J]. Expert Rev Clin Pharmacol, 2013,6 (2) : 197-219.

引证文献14

二级引证文献141

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部